Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma

*The trial information contained on this page was imported from Click here to view this trial on

Back to search
Print this study
Full Title:
A Phase III Non-Inferiority Randomized Controlled Trial of Fixed Duration Versus Continuous Daratumumab Among Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma
Myeloma stage or condition:
Multiple Myeloma
Study phase:
Phase 3
Currently, daratumumab, lenalidomide, and dexamethasone are given continuously (non-stop). Some recent observations suggest that stopping daratumumab after about a year and a half of treatment may work just as well as giving it continuously with lenalidomide and dexamethasone. This study is being done to answer the question: is less daratumumab treatment as good as more?
Detailed Description:
The usual approach for people with myeloma who are not having a stem cell transplant is treatment with the combination of daratumumab, lenalidomide, and dexamethasone. These drugs are given continuously until they are no longer effective or cause major side effects. Those that decide to take part in this study, will be randomly placed in one of two groups. If in the usual care group, patients will continue all the myeloma medicines currently being taken. If in the experimental group, patients will stop the daratumumab injection, and continue taking the myeloma tablets currently being taken. Regardless of which group, patients will stay on treatment indefinitely as long they are benefiting from it.
Drug : Daratumumab

Dose determined at enrollment

Drug : Lenalidomide

Dose determined at enrollment

Drug : Dexamethasone

Dose determined at enrollment

Study Arms:
Experimental : Lenalidomide & Dexamethasone
Active Comparator : Daratumumab, Lenalidomide & Dexamethasone
Standard of Care
Study Type:
Study Design:
Allocation: Randomized
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Masking: None (Open Label)
Recruitment status:
Eligibility criteria:
Inclusion Criteria:
  • Participants with newly diagnosed multiple myeloma that are transplant-ineligible
  • Measurable disease at the time of diagnosis, as defined by at least one of the following criteria: Serum M-protein ≥ 5 g/L; Urine M-protein ≥ 200 mg/24 hours; Involved serum free light chain measurement ≥ 100 mg/L, provided serum FLC ration is abnormal; For IgA patients whose disease can only be reliably measured by serum quantitative immunoglobulin ≥ 750 mg/dL
  • Received daratumumab-lenalidomide-dexamethasone for 18-20 cycles
  • Obtained at least a partial response per the standard 2016 IMWG criteria
  • ECOG performance status 0-3
  • Participant is able (i.e. sufficiently fluent) and willing to complete the quality of life and/or health utility questionnaires in English, French, or a provided validated language.
  • Participant consent must be appropriately obtained in accordance with applicable local and regulatory requirements.
  • Participants must be accessible for treatment and follow-up.
  • In accordance with CCTG policy, protocol treatment is to begin within 2 working days of participant enrollment.
  • Participants of childbearing potential must have agreed to use a highly effective contraceptive method.
Exclusion Criteria:
  • Known history of concurrent amyloid light chain amyloidosis, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), and Waldenstrom's macroglobulinemia.
  • Patients receiving concurrent treatment with other anti-cancer therapy that would impact the ability to comply with protocol treatment are ineligible. Note: Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of protocol treatment are eligible for this trial
  • Active, uncontrolled bacterial, fungal, or viral infection within 7 days prior to enrollment.
  • Known human immunodeficiency virus (HIV) with CD4 count < 350 cells/microliter. Note that patients who are HIV positive are eligible, provided:
  • They are under treatment with antiretroviral therapy for at least 4 weeks prior to enrollment, with acceptable pharmacokinetic interactions and minimal overlapping toxicity with protocol therapy AND
  • HIV viral load must be < 400 copies/ml within 16 weeks prior to enrollment AND
  • No history of opportunistic infections within the past year.
Locations / Centres:

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario – Recruiting

Name: Annette Hay
Phone: 613-533-6430
Email: [email protected]
First posted:
Actual start date:
April 10, 2024
Last updated:
Estimated enrollment:
Estimated completion date:
Estimated primary completion date:
Multiple Myeloma
18 Years-N/A
Accepts healthy volunteers:
Listed location countries:
NCT number:
Other study ID numbers:
Has Data monitoring committee:
U.S. FDA-regulated product:
IPD Sharing Statement :
Responsible party:
Study sponsor:
Canadian Institutes of Health Research (CIHR)
Myeloma Canada
Canadian Cancer Trials Group
Hira Mian Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario Canada
Protocol Registration and Results System:
Verification date: